Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here
The FDA has incorporated PD-L1 status into the labels for pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma.
Source: OncLive
Your Technology Source, Your Technology Team
Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more
Contact Us: contact@crwetech.com
Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure
CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform
Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!
Contact Us: contact@crweworld.com
Your Technology Source, Your Technology Team
Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more
Contact Us: contact@crwetech.com
Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure
CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform
Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!
Contact Us: contact@crweworld.com
